Biogen (BIIB) Approves $5B Stock Buyback Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
July 21, 2016 7:00 AM EDTSecond quarter 2016 GAAP diluted EPS rise 22%; Non-GAAP diluted EPS rise 23%
Company raises financial guidance for the year and authorizes $5 billion share repurchase program
George A. Scangos, Ph.D., to step down as CEO
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2016 financial results, including:
Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide revenues from the Companys multiple sclerosis (MS) and hemophilia... More